We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byPerry Sund
Modified over 2 years ago
Opioid Dependence During Pregnancy Michelle Lofwall, M.D. University of Kentucky 1 © AMSP 2009
Challenging to Treat MDs have inadequate training MDs have inadequate training Medical & legal system prejudices Medical & legal system prejudices State reporting requirements State reporting requirements Doctor-patient alliance problems Doctor-patient alliance problems 2 © AMSP 2009
What You Need to Know Punishment ≠ effective deterrent Punishment ≠ effective deterrent Comprehensive treatment works! Comprehensive treatment works! 3x in mom’s opiate use 3x in mom’s opiate use Prenatal care Prenatal care 3x low birth weight (LBW: <2500 grams) 3x low birth weight (LBW: <2500 grams) Perinatal HIV transmission to <2% Perinatal HIV transmission to <2% 2x maternal custody in 1 st yr 2x maternal custody in 1 st yr 3 © AMSP 2009
This Lecture Reviews Definitions Definitions Causes, course, prevalence & comorbidity Causes, course, prevalence & comorbidity Medical complications Medical complications Treatment Treatment 4 © AMSP 2009
Abuse ≥ 1 of: Abuse ≥ 1 of: Obligations Obligations Hazardous use Hazardous use Legal Legal Interpersonal problems Interpersonal problems Dependence ≥ 3 of: Dependence ≥ 3 of: Tolerance Tolerance Withdrawal Withdrawal Amounts or more time Amounts or more time Desire or unable cut down Desire or unable cut down Time get, use, or recover Time get, use, or recover Non-drug activities Non-drug activities Physical/psychological problems Physical/psychological problems Abuse & Dependence 6 © AMSP 2009
Occurs with / use OR opioid antagonist Occurs with /no opioid use OR opioid antagonist ≥ 3 of: ≥ 3 of: Dysphoria (unhappy) Dysphoria (unhappy) Nausea or vomit Nausea or vomit Muscle aches Muscle aches Lacrimation (watery eyes) or rhinorrhea (runny nose) Lacrimation (watery eyes) or rhinorrhea (runny nose) Diarrhea Diarrhea Opioid Withdrawal Yawning Yawning Fever Fever Insomnia Insomnia Mydriasis (big pupils), Mydriasis (big pupils), piloerection (goose bumps), or sweating 7 © AMSP 2009
This Lecture Reviews Definitions ✓ Definitions ✓ Causes, course, prevalence & comorbidity Causes, course, prevalence & comorbidity Medical complications Medical complications Treatment Treatment 8 © AMSP 2009
Etiology 50% Genes 50% Environment Availability Peer use Drug-using partners Hx victimization 9 © AMSP 2009
Chronic Relapsing Course >50% relapse >50% relapse >90% use opioids before pregnancy >90% use opioids before pregnancy 20x mortality vs. Ø substance disorder dx 20x mortality vs. Ø substance disorder dx 10 © AMSP 2009
Prevalence of Opiate Use Opiate % Opiate + 11 © AMSP 2009
>10% Axis I LBW with mood disorder Other Drugs & Psych Dxs 12 © AMSP 2009 > 90% Cigs LBW Premature SIDS Stillbirths >10% Cocaine Placental abruption Premature
Complex Social Problems >50% single moms & unemployed >50% single moms & unemployed >25% hx of physical/sexual abuse >25% hx of physical/sexual abuse Low socioeconomic status Low socioeconomic status Adversely affects pregnancy Adversely affects pregnancy Prenatal care Prenatal care Direct harm Direct harm 13 © AMSP 2009
Risky Behaviors Sharing needles, unprotected sex, dealing Sharing needles, unprotected sex, dealing Mom’s infections risk of: Mom’s infections risk of: Premature contractions & labor Premature contractions & labor Breakdown fetal membranes & abortion Breakdown fetal membranes & abortion Difficult to separate out opioid effects Difficult to separate out opioid effects 14 © AMSP 2009
This Lecture Reviews Definitions ✓ Definitions ✓ Causes, course, prevalence & comorbidities ✓ Causes, course, prevalence & comorbidities ✓ Medical complications Medical complications Treatment Treatment 15 © AMSP 2009
Maternal & Fetal Problems Multifactorial etiology Multifactorial etiology HIV: 25% transmit HIV: 25% transmit Hep C: ~5% transmit Hep C: ~5% transmit Endocarditis heart failure hypoxia Endocarditis heart failure hypoxia Nutritional deficiency – e.g., 25% Fe-defic Nutritional deficiency – e.g., 25% Fe-defic 16 © AMSP 2009
Fetal Hypoxia Unstable fetal environment 17 © AMSP 2009
Newborn Birth Outcomes ~50% LBW (~20% with rx) ~50% LBW (~20% with rx) Death Death ~25% HIV (<2% with rx) ~25% HIV (<2% with rx) Meconium aspiration (stool inhaled into lungs) Meconium aspiration (stool inhaled into lungs) ~10% Microcephaly (small head) ~10% Microcephaly (small head) 18 © AMSP 2009
Neonatal Abstinence Syndrome (NAS) 19 © AMSP 2009
NAS Definition Central nervous system excitability Central nervous system excitability Autonomic nervous system Autonomic nervous system GI system malfunction GI system malfunction Respiratory distress Respiratory distress 20 © AMSP 2009
NAS Time course depends on: Time course depends on: Opioid half-life (T ½) Opioid half-life (T ½) Fetal opioid storage & metabolism Fetal opioid storage & metabolism Risk factors: Risk factors: Opioid dependent mom 70% chance NAS Opioid dependent mom 70% chance NAS Smoking severity Smoking severity Prematurity severity Prematurity severity 21 © AMSP 2009
22 © AMSP 2009
This Lecture Reviews Definitions ✓ Definitions ✓ Causes, course, prevalence & comorbidities ✓ Causes, course, prevalence & comorbidities ✓ Medical complications ✓ Medical complications ✓ Treatment Treatment 23 © AMSP 2009
4 Treatments Reviewed Psychosocial rx without medication Psychosocial rx without medication Methadone maintenance (MM) Methadone maintenance (MM) Methadone-assisted withdrawal Methadone-assisted withdrawal Buprenorphine (Subutex®) maintenance Buprenorphine (Subutex®) maintenance 24 © AMSP 2009
Psychosocial Interventions Cornerstone Cornerstone Therapeutic alliance Therapeutic alliance Expect demanding & resistant behavior Expect demanding & resistant behavior Complete assessment Complete assessment Assist with all problems Assist with all problems 25 © AMSP 2009
Methadone Maintenance Long T ½ (27 hrs), synthetic opioid agonist Long T ½ (27 hrs), synthetic opioid agonist Strict federal regulations Strict federal regulations Opioid dependent > 1 yr (unless preg) Opioid dependent > 1 yr (unless preg) > 18 yrs unless parental consent/failed rx > 18 yrs unless parental consent/failed rx Daily visits x 90 days Daily visits x 90 days 26 © AMSP 2009
Many Treatment Goals Mother: Mother: /stop withdrawal /stop withdrawal /stop drug use /stop drug use Prenatal/med/psych rx Prenatal/med/psych rx Psychosocial probs Psychosocial probs Supportive network Supportive network Parenting skills Parenting skills 27 © AMSP 2009
Many Treatment Goals Fetus/neonate Fetus/neonate Stable intrauterine environment Stable intrauterine environment Stop intox/withdrawal cycles Stop intox/withdrawal cycles Deliver term/healthy newborn Deliver term/healthy newborn + maternal/fetal bond + maternal/fetal bond 28 © AMSP 2009
Components of MM Treatment Multidisciplinary team Multidisciplinary team Individual & group counseling Individual & group counseling Parenting classes Parenting classes Daily oral methadone dosing Daily oral methadone dosing Start at 30 mg (40 mg max day 1) Start at 30 mg (40 mg max day 1) > 50 mg maintenance dose > 50 mg maintenance dose Blocks + illicit opioid effects Blocks + illicit opioid effects Prevents withdrawal Prevents withdrawal 29 © AMSP 2009
MM Benefits 3x in mom’s opiate use 3x in mom’s opiate use Prenatal care Prenatal care 3x LBW 3x LBW Perinatal HIV transmission to <2% Perinatal HIV transmission to <2% 2x maternal custody of newborn 2x maternal custody of newborn 30 © AMSP 2009
MM Limitations Availability Availability Limited patient acceptance Limited patient acceptance Does not incidence of NAS Does not incidence of NAS Report of fine motor skill problems Report of fine motor skill problems 31 © AMSP 2009
Methadone-assisted Withdrawal 1970’s = standard rx until fetal deaths 1970’s = standard rx until fetal deaths Utilized if MM not available or accepted Utilized if MM not available or accepted Goals: Goals: Mother/fetus opioid withdrawal Mother/fetus opioid withdrawal Achieve opioid free state in mom/fetus Achieve opioid free state in mom/fetus Deliver term, healthy fetus with no NAS Deliver term, healthy fetus with no NAS 32 © AMSP 2009
Components of Withdrawal Treatment Inpatient Inpatient OB monitors fetus daily for distress OB monitors fetus daily for distress Stabilize on methadone then taper dose Stabilize on methadone then taper dose If fetal distress – slow taper, dose If fetal distress – slow taper, dose 3 & 7 day tapers at specialty units 3 & 7 day tapers at specialty units Discharge Discharge Con’t outpatient rx to maintain abstinence Con’t outpatient rx to maintain abstinence 33 © AMSP 2009
Withdrawal Outcomes >50% relapse >50% relapse Problem > opioid withdrawal Problem > opioid withdrawal Problem = medical & psychosocial Problem = medical & psychosocial Compared to MM, detox alone results in: Compared to MM, detox alone results in: 2x + urine drug test at delivery 2x + urine drug test at delivery 5x days in trt 5x days in trt 6 fewer OB appts 6 fewer OB appts No diff in NAS or birth outcomes No diff in NAS or birth outcomes 34 © AMSP 2009
Buprenorphine Maintenance 2002 approved rx for non-preg opioid depend 2002 approved rx for non-preg opioid depend Partial opioid agonist Partial opioid agonist Enhanced safety profile Enhanced safety profile T ½ = 37 hrs T ½ = 37 hrs Office-based Office-based 35 © AMSP 2009
Buprenorphine Maintenance Must become qualified to prescribe Must become qualified to prescribe Potential advantages Potential advantages Similar outcomes as MM Similar outcomes as MM Large on-going clinical trial Large on-going clinical trial 36 © AMSP 2009
This Lecture Reviewed Definitions ✓ Definitions ✓ Causes, course, prevalence & comorbidities ✓ Causes, course, prevalence & comorbidities ✓ Medical complications ✓ Medical complications ✓ Treatment ✓ Treatment ✓ 37 © AMSP 2009
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine.
Effective Risk Management Strategies in Outpatient Methadone Treatment: Clinical Guidelines and Liability Prevention Curriculum Module 9 Special Populations.
Opioid Abuse and Dependence
Moms on Meds Substance Abuse During Pregnancy: Jennifer Anderson Maddron, M.D.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Opiates and Pain PAIN Spinal Cord Substance P BRAIN Opiates.
Specific issues in drug use and pregnancy. Pregnant women who use drugs (RCOG, 2010) One of the challenges for pregnant women who use drugs is that they.
Putting the Pieces Together Perspectives from an Opioid Addiction Treatment Program.
Neonatal Abstinence Syndrome
OBJECTIVES Learn about types of opioids and associated withdrawal symptoms Learn what medications are available to treat opioid addiction Understand.
Substance Use & Abuse in Pregnancy Janet L. Mitchell, M.D., M.P.H., F.A.C.O.G. Consultant on Women’s Health Addiction Research & Treatment Corporation.
Discuss why pregnant adolescents are considered high risk Special Considerations in regards to Use of force Restraints Transportation Substance.
Instructor: Jose Davila
Treatment of opioid dependence during pregnancy Judith Martin, MD Medical Director The 14 th Street Clinic, Oakland
HIV and Injection Drug Use
Drug Treatment Issues in Drug-Dependent, Pregnant Women Hendrée E. Jones, Ph.D. Department of Psychiatry and Behavioral Sciences Johns Hopkins University.
for the PRITE is proud to present And Now Here Is The Host... Insert Name Here.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
1 HIV and Injection Drug Use HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Opioid Dependence Anne Kalvik Pearl Isaac. Learning Objectives 1.To develop an understanding of opioid dependence issues including tolerance, abuse, toxicity,
OPIATES Kendell Hodgden. DEFINES/DESCRIBES OPIATES referred to as narcotics a group of drugs which are used medically to relieve pain have a high potential.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
O PIOID WITHDRAWALS. W ITHDRAWALS Withdrawals Detoxification is relatively a simple process - achieved by large percentage seeking Rx.
V.Sideri, C.Vliora, A.Daskalaki, P.Mexi-Bourna, K.Kleanthous, M.Soulioti, G. Kyrkou, N.Bournas, V.Papaevangelou 3 rd Pediatric Clinic of the University.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Treating Pregnant Opioid Dependent Women: Examining Buprenorphine and Methadone Hendrée E. Jones, Ph.D. Associate Professor Department of Psychiatry and.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Opioids Unless otherwise indicated, the answers are from DSM-IV-TR and APA Practice Guidelines, AJP Supplement, August, As of 3Aug06.
13 Principles of Effective Addictions Treatment
Pregnancy and Drug Abuse Eva Janecek-Rucker. Learning Objectives 1.To develop a knowledge base of the effects of substances of abuse (e.g., alcohol, cocaine,
Lisa Hackenmueller Caitlin McNamara Katrina Awker.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Copyright Alcohol Medical Scholars Program1 The Relationships Between Alcohol Use Disorders and Nicotine Dependence Margaret Rukstalis, M.D. University.
IMPACT OF SUBSTANCE ABUSE ON THE MOTHER AND FETUS Siva Thiagarajah, M.D. Gary D. Helmbrecht, M.D. Prenatal Diagnosis Center Charlottesville, VA.
Chapter 16 Addictive Disorders. Abuse Use of a substance that falls outside of medical necessity or social acceptance resulting in adverse effects to.
Preterm Labor & Preterm Birth Family Medicine Specialist CME Vientiane, Lao PDR December 10 – 12, 2008.
Clinical aspects Module 4. Steps Assessment Criteria for treatment Treatment plan Induction Monitoring Evaluation.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
“HEROIN” Presented by: Neva Chauppette, Psy.D P.O. Box 6234, Woodland Hills, CA cell / fax CA License PSY14524
Teratogens Child Psych II. What is a Teratogen? Definition: A teratogen is an environmental agent that can adversely affect the unborn child, thus producing.
September 2015 PREGNANCY. Awareness of the range of substance use disorders in pregnancy Understand how different substances affect the fetus Identification.
John McCarthy, M.D. Executive/Medical Director, Bi-Valley Medical Clinic, Sacramento.
RISE Recovery & Integration Service Substance Use & Pregnancy Liz Thompson Families and Communities Manager.
Incorporating Preconception Health into MCH Services
© 2017 SlidePlayer.com Inc. All rights reserved.